Devyser Diagnostics
Devyser Diagnostics AB is a Swedish diagnostic technology company developing DNA testing kits for hereditary diseases, oncology, and post-transplant monitoring. The company manufactures NGS diagnostic reagent kits enabling rapid target DNA sequencing, including Devyser Accept-cfDNA for transplant monitoring and Devyser BRCA for cancer risk screening. Main revenue drivers consist of commercial sales of diagnostic test kits and reagents alongside specialized clinical testing services. Devyser Diagnostics serves clinical genetics laboratories, hospital pathology departments, transplant centers, and oncology clinics across Europe, North America, and Asia. The company holds a specialized niche position in European NGS-based genetic testing and transplant monitoring diagnostics. Headquartered in Stockholm, Sweden, Devyser Diagnostics AB is listed on Nasdaq First North Premier Growth Market.
4 of the funds FundTelligence covers report a position in Devyser Diagnostics.
- Legal name
- Devyser Diagnostics AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 4
- Exposure themes
- Genetic Testing, Molecular Diagnostics, Precision Medicine & Genomics
Funds holding Devyser Diagnostics
- Case Gaia Microcap — Case · 1.37 % (full portfolio disclosed, June 2026)
- Schroder ISF Nordic Micro Cap — Schroders · 1.23 % (full portfolio disclosed, June 2026)
- Aktiespararna Småbolag Edge — Cicero Fonder · 1.22 % (full portfolio disclosed, June 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.15 % (full portfolio disclosed, October 2026)